Key business insights
-
HCG employs multidisciplinary approach for the disease diagnosis and treatment wherein specialists from multiple disciplines come together to accurately evaluate the patient information, standardize the treatment approach and create efficiencies that will eventually lead to effective disease management.
-
Recently acquired next generation sequence in genomics which is a high-end sequencer and in the process of acquiring circulating tumor cell platform.
-
Brought in high-end technology including Linear Accelerators and Positron Emission Tomography to Tier II and Tier III cities and towns.
-
Triesta Sciences, a unit of HCG is the stateof-the-art, one-stop solution for cancer diagnostics, genomics (next-generation sequencing-based diagnostics) biomarker and translational research, laboratory services and clinical research services. Based out of Bangalore, Triesta Sciences is an integration of laboratory services, research and development and clinical research with a focus on innovation, quality and accuracy for better diagnosis and prognosis of cancer. Triesta reference laboratory is the leading CAP & NABL accredited high-end oncology diagnostic laboratory service provider in the country offering a comprehensive range of routine to highly specialized diagnostic tests for hospitals, medical institutions within India and overseas.
-
Through a pioneering industry initiative, we have brought healthcare training and medical education to the Metaverse by publishing 200+ hours of virtual reality content across multiple subspecialties.
-
During the year under review, we have added over 40 oncologists, taking the total number of doctors in our team to over 450, which is the largest in the Oncology space in India
-
Post pandemic, we are seeing a rise in the number of patients covered by some form of insurance which augurs well for making cancer care more accessible and affordable for the community going forward
-
Coming to our financial performance for FY 22, our revenue from operations grew by 38% YoY to H 13,978 Mn, in comparison to H 10,134 Mn in FY21. With our focused efforts and local marketing activities, we have been able to grow our new centres revenues by 65% as compared to FY21. Revenues from existing centres grew by 31% on Y-o-Y basis. We reported robust year-on-year growth with an all-time record revenue across all four quarters of the financial year.
-
Our operating EBITDA grew from H 1,266 Mn in FY21 to H 2,380 Mn, registering a phenomenal
growth of 88% YoY. -
Profit of H 537 Mn, against a loss of H (1,935) Mn in the previous year. Alongside, we have also been working on strengthening our balance sheet and have been able to reduce our net debt from H 2,882 Mn as on March 31, 2021, to H 1,901 Mn as on March 31, 2022.
-
Largest player with Oncology focus in India with a cumulative operational bed capacity of 1,702 beds as on March 31, 2022. With 21 comprehensive cancer centres across 18 metro & non-metro cities
in India, we enjoy leadership position in 13 of those locations
Subscribe To Our Free Newsletter |